Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status. in British journal of cancer / Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966-x.
2025
AO Ordine Mauriziano
AO Ordine Mauriziano
Tipo pubblicazione
Journal Article
Autori/Collaboratori (20)Vedi tutti...
Pignata S
Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy. s.pignata@istitutotumori.na.it.
Oza A
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Hall G
Leeds Institute of Medical Research, St James's University Hospital, Leeds, UK.
et alii...
Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy. s.pignata@istitutotumori.na.it.
Oza A
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Hall G
Leeds Institute of Medical Research, St James's University Hospital, Leeds, UK.
et alii...
Abstract
BACKGROUND: The open-label, single-arm, multicentre ORZORA trial (NCT02476968) evaluated maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) with a germline (g) or somatic (s) BRCA1 and/or BRCA2 mutation (BRCAm) or a non-BRCA homologous recombination repair mutation (non-BRCA HRRm). METHODS: Patients were in response to platinum-based chemotherapy after ?2 prior lines of treatment and underwent prospective central screening for tumour BRCA status, then central gBRCAm testing to determine sBRCAm or gBRCAm status. An exploratory cohort evaluated non-BRCA HRRm in 13 predefined genes. Patients received olaparib 400?mg (capsules) twice daily until investigator-assessed disease progression. Secondary endpoints included overall survival (OS) and safety. RESULTS: 177 patients received olaparib. At the final data cutoff (25 June 2021), median OS from study enrolment was 46.8 (95% confidence interval [CI] 37.9-54.4), 43.2 (31.7-NC [not calculated]), 47.4 (37.9-NC) and 44.9 (28.9-NC) months in the BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts, respectively. No new safety signals were identified. CONCLUSION: Maintenance olaparib showed consistent clinical activity in the BRCAm and sBRCAm cohorts; exploratory analysis suggested similar activity in the non-BRCA HRRm cohort. These findings highlight that patients with PSR OC, beyond those with gBRCAm, may benefit from maintenance olaparib.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 40097725
DOI : 10.1038/s41416-025-02966-x